Produção Nacional
Revisado por pares
TCTP as a therapeutic target in melanoma treatment
2017; Springer Nature; Volume: 117; Issue: 5 Linguagem: Inglês
10.1038/bjc.2017.230
ISSN1532-1827
AutoresMarianna Bóia-Ferreira, Alana Basílio, Azumi Hamasaki, F H Matsubara, Márcia Helena Appel, Cleber Rafael Vieira da Costa, Robert Amson, Adam Telerman, Olga Meiri Chaim, Sílvio Sanches Veiga, Andrea Senff‐Ribeiro,
Tópico(s)Neuropeptides and Animal Physiology
ResumoTranslationally controlled tumour protein (TCTP) is an antiapoptotic protein highly conserved through phylogeny. Translationally controlled tumour protein overexpression was detected in several tumour types. Silencing TCTP was shown to induce tumour reversion. There is a reciprocal repression between TCTP and P53. Sertraline interacts with TCTP and decreases its cellular levels. We evaluate the role of TCTP in melanoma using sertraline and siRNA. Cell viability, migration, and clonogenicity were assessed in human and murine melanoma cells in vitro. Sertraline was evaluated in a murine melanoma model and was compared with dacarbazine, a major chemotherapeutic agent used in melanoma treatment. Inhibition of TCTP levels decreases melanoma cell viability, migration, clonogenicity, and in vivo tumour growth. Human melanoma cells treated with sertraline show diminished migration properties and capacity to form colonies. Sertraline was effective in inhibiting tumour growth in a murine melanoma model; its effect was stronger when compared with dacarbazine. Altogether, these results indicate that sertraline could be effective against melanoma and TCTP can be a target for melanoma therapy.
Referência(s)